Cannabis use is increasing with the shifts in legality and public perceptions in the United States.1 Studies have reported improvement in insulin sensitivity and pancreatic beta cell function with cannabis use,2,3 generating widespread media attention suggesting cannabis as a potential therapeutic agent for treatment of type 2 diabetes. By contrast, we published a case series4 reporting recurrent diabetic ketoacidosis (DKA) with cannabis use in patients with type 1 diabetes (T1D). Because little is known about cannabis use and its contribution to DKA in T1D, we investigated the characteristics of cannabis use among adults with T1D and the association of cannabis use with DKA.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes. JAMA Intern Med. 2019;179(1):115–118. doi:10.1001/jamainternmed.2018.5142
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: